Open-Label Extension of EryDex Study IEDAT-04-2022

NCT06664853 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

101

Enrollment

INDUSTRY

Sponsor class

Stopped eDSP development discontinued

Conditions

Ataxia Telangiectasia

Interventions

DRUG: Dexamethasone sodium phosphate

Sponsor

Quince Therapeutics S.p.A.

Collaborators

[object Object]